SEC Info - Shire plc - ‘10-K’ for 12/31/09

SEC Info℠

Home

Help

Please Sign In

Shire plc – ‘10-K’ for 12/31/09 – ‘XML.R37’

On: Friday, 2/26/10, at 12:40pm ET · For: 12/31/09 · Accession #: 950103-10-520 · File #: 0-29630

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/26/10  Shire plc                         10-K       12/31/09   62:8.1M                                   Davis Polk & … LLP 01/FA

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.87M 
 2: EX-10.26    Material Contract                                   HTML     37K 
 3: EX-21       Subsidiaries List                                   HTML     47K 
 4: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 5: EX-23.2     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
47: XML         IDEA XML File -- Definitions and References          XML    131K 
55: XML         IDEA XML File -- Filing Summary                      XML     94K 
52: XML.R1      Document And Entity Information                      XML     89K 
53: XML.R2      Consolidated Balance Sheets                          XML    268K 
32: XML.R3      Consolidated Balance Sheets (Parentheticals)         XML     57K 
37: XML.R4      Consolidated Balance Sheets (Parentheticals in       XML     33K 
                GBP)                                                             
45: XML.R5      Consolidated Statements of Operations                XML    365K 
44: XML.R6      Consolidated Statements of Operations                XML     51K 
                (Parentheticals)                                                 
59: XML.R7      Consolidated Statement of Changes in Shareholders'   XML   1.03M 
                Equity                                                           
22: XML.R8      Consolidated Statements of Comprehensive Income      XML    122K 
43: XML.R9      Components of Accumulated Other Comprehensive        XML     51K 
                Income                                                           
20: XML.R10     Consolidated Statements of Comprehensive Income      XML     59K 
                (Parentheticals)                                                 
19: XML.R11     Consolidated Statements of Cash Flows                XML    545K 
31: XML.R12     Description Of Operations                            XML     35K 
49: XML.R13     Summary Of Significant Accounting Policies           XML     80K 
33: XML.R14     Business combinations                                XML     79K 
34: XML.R15     Termination costs                                    XML     38K 
41: XML.R16     Gain on sale of product rights                       XML     35K 
62: XML.R17     Reorganization costs                                 XML     43K 
29: XML.R18     Intergration and Acquisition costs                   XML     35K 
15: XML.R19     Accounts receivable, net                             XML     38K 
36: XML.R20     Inventories                                          XML     37K 
48: XML.R21     Assets held for sale                                 XML     35K 
25: XML.R22     Prepaid expenses and other current assets            XML     37K 
46: XML.R23     Investments                                          XML     40K 
35: XML.R24     Property Plant and Equipment, net                    XML     38K 
58: XML.R25     Goodwill                                             XML     39K 
51: XML.R26     Other intangible assets, net                         XML     43K 
38: XML.R27     Accounts payable and accrued expenses                XML     43K 
42: XML.R28     Other current liabilities                            XML     37K 
18: XML.R29     Long-term debt                                       XML     40K 
21: XML.R30     Other long-term debt                                 XML     36K 
26: XML.R31     Other non-current liabilities                        XML     37K 
30: XML.R32     Derivative instruments                               XML     45K 
40: XML.R33     Fair value measurement                               XML     53K 
50: XML.R34     Commitments and contingencies                        XML     56K 
17: XML.R35     Shareholders Equity                                  XML     41K 
23: XML.R36     Earnings per share                                   XML     52K 
54: XML.R37     Segmental reporting                                  XML     97K 
57: XML.R38     Interest expense                                     XML     36K 
39: XML.R39     Other income (expenses), net                         XML     39K 
60: XML.R40     Retirement benefits                                  XML     34K 
24: XML.R41     Taxation                                             XML     86K 
61: XML.R42     Share-based compensation plans                       XML     71K 
28: XML.R43     Restatement of previously issued financial           XML     35K 
                statements                                                       
16: XML.R44     Income Access Share Trust Financial Statements       XML     62K 
27: XML.R45     Valuation and Qualifying Accounts Schedule           XML     45K 
56: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    206K 
 9: EX-101.INS  XBRL Instance -- shpgf-20091231                      XML    826K 
11: EX-101.CAL  XBRL Calculations -- shpgf-20091231_cal              XML    203K 
12: EX-101.DEF  XBRL Definitions -- shpgf-20091231_def               XML     86K 
13: EX-101.LAB  XBRL Labels -- shpgf-20091231_lab                    XML    822K 
14: EX-101.PRE  XBRL Presentations -- shpgf-20091231_pre             XML    468K 
10: EX-101.SCH  XBRL Schema -- shpgf-20091231                        XSD     99K

‘XML.R37’ — Segmental reporting

This Financial Report is an XBRL XML File.

<?xml version="1.0" encoding="windows-1252"?>

<hasSegments> false </hasSegments>

<ReportName> Segmental reporting </ReportName>

<LabelColumn> false </LabelColumn>

</Labels>

<hasSegments> false </hasSegments>

<hasScenarios> false </hasScenarios>

<Units>

<Unit>

<UnitType> Divide </UnitType>

</NumeratorMeasure>

<MeasureSchema> http://www.xbrl.org/2003/instance </MeasureSchema>

<MeasureValue> shares </MeasureValue>

<MeasureNamespace> xbrli </MeasureNamespace>

</DenominatorMeasure>

</Unit>

<Unit>

<UnitID> shares </UnitID>

<UnitType> Standard </UnitType>

<MeasureSchema> http://www.xbrl.org/2003/instance </MeasureSchema>

<MeasureValue> shares </MeasureValue>

<MeasureNamespace> xbrli </MeasureNamespace>

</StandardMeasure>

</Unit>

<Unit>

<UnitType> Standard </UnitType>

</StandardMeasure>

</Unit>

</Units>

</Column>

</Columns>

<Rows>

<Row>

<Label> NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </Label>

<ElementName> shpgf_NotesToTheConsolidatedFinancialStatementsAbstract </ElementName>

<ElementPrefix> shpgf </ElementPrefix>

<IsBaseElement> false </IsBaseElement>

<PeriodType> duration </PeriodType>

<ElementDataType> string </ElementDataType>

<ShortDefinition> No definition available. </ShortDefinition>

<IsReportTitle> false </IsReportTitle>

<IsSegmentTitle> false </IsSegmentTitle>

<IsSubReportEnd> false </IsSubReportEnd>

<IsCalendarTitle> false </IsCalendarTitle>

<IsTuple> false </IsTuple>

<IsBeginningBalance> false </IsBeginningBalance>

<IsEndingBalance> false </IsEndingBalance>

<IsEPS> false </IsEPS>

<Cells>

<Cell>

<ShowCurrencySymbol> false </ShowCurrencySymbol>

<IsNumeric> false </IsNumeric>

<hasSegments> false </hasSegments>

<hasScenarios> false </hasScenarios>

</Cell>

</Cells>

<ElementDefenition> No definition available. </ElementDefenition>

<IsTotalLabel> false </IsTotalLabel>

</Row>

<Row>

<Label> Segmental reporting </Label>

<ElementName> us-gaap_SegmentReportingDisclosureTextBlock </ElementName>

<PeriodType> duration </PeriodType>

<ElementDataType> string </ElementDataType>

<ShortDefinition> No definition available. </ShortDefinition>

<IsReportTitle> false </IsReportTitle>

<IsSegmentTitle> false </IsSegmentTitle>

<IsSubReportEnd> false </IsSubReportEnd>

<IsCalendarTitle> false </IsCalendarTitle>

<IsTuple> false </IsTuple>

<IsAbstractGroupTitle> false </IsAbstractGroupTitle>

<IsBeginningBalance> false </IsBeginningBalance>

<IsEndingBalance> false </IsEndingBalance>

<IsEPS> false </IsEPS>

<Cells>

<Cell>

<ShowCurrencySymbol> false </ShowCurrencySymbol>

<IsNumeric> false </IsNumeric>

<div style="font-size:12pt">26. Segmental reporting Shire’s internal financial reporting is in line with its business unit and management reporting structure based on two segments: Specialty Pharmaceuticals (which aggregates ADHD, GI and other Specialty Pharmaceutical products) and HGT. The Specialty Pharmaceuticals and HGT reportable segments represent the Company’s revenues and costs in respect of currently promoted and sold products, together with the costs of developing projects for future commercialization. ‘All Other’ has been included in the table below in order to reconcile the two operating segments to the total consolidated figures. The Company evaluates performance based on revenue and operating income. The Company does not have inter-segment transactions. Assets that are directly attributable or allocable to the segments have been separately disclosed. <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="36" width="276" align="left"> </td><td height="36" width="122" align="right">Specialty Pharmaceuticals</td><td height="36" width="103" align="right">HGT</td><td height="36" width="103" align="right">All Other</td><td height="36" width="103" align="right">Total</td></tr><tr><td height="20" width="276" align="right">2009 </td><td height="20" width="122" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Product sales</td><td height="20" width="122" align="right">2,138.2 </td><td height="20" width="103" align="right">555.5 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">2,693.7 </td></tr><tr><td height="20" width="276" align="left">Royalties</td><td height="20" width="122" align="right">127.2 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right"> 165.3 </td><td height="20" width="103" align="right">292.5 </td></tr><tr><td height="20" width="276" align="left">Other revenues</td><td height="20" width="122" align="right">9.9 </td><td height="20" width="103" align="right">2.6 </td><td height="20" width="103" align="right"> 9.0 </td><td height="20" width="103" align="right">21.5 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total revenues</td><td height="20" width="122" align="right">2,275.3 </td><td height="20" width="103" align="right">558.1 </td><td height="20" width="103" align="right"> 174.3 </td><td height="20" width="103" align="right">3,007.7 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="17" width="276" align="left"> </td><td height="17" width="122" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Cost of product sales(1) (2)</td><td height="20" width="122" align="right">299.3 </td><td height="20" width="103" align="right">88.7 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">388.0 </td></tr><tr><td height="20" width="276" align="left">Research and development(1) (2)</td><td height="20" width="122" align="right">375.0 </td><td height="20" width="103" align="right">257.2 </td><td height="20" width="103" align="right">6.1 </td><td height="20" width="103" align="right">638.3 </td></tr><tr><td height="20" width="276" align="left">Selling, general and administrative(1) (2)</td><td height="20" width="122" align="right">954.4 </td><td height="20" width="103" align="right">208.7 </td><td height="20" width="103" align="right">179.5 </td><td height="20" width="103" align="right">1,342.6 </td></tr><tr><td height="20" width="276" align="left">Gain on sale of product rights</td><td height="20" width="122" align="right">(6.3)</td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">(6.3)</td></tr><tr><td height="20" width="276" align="left">IPR&D charge</td><td height="20" width="122" align="right">- </td><td height="20" width="103" align="right">1.6 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">1.6 </td></tr><tr><td height="20" width="276" align="left">Reorganization costs</td><td height="20" width="122" align="right">12.7 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">12.7 </td></tr><tr><td height="20" width="276" align="left">Integration and acquisition costs</td><td height="20" width="122" align="right">2.9 </td><td height="20" width="103" align="right">7.7 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">10.6 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total operating expenses</td><td height="20" width="122" align="right">1,638.0 </td><td height="20" width="103" align="right">563.9 </td><td height="20" width="103" align="right">185.6 </td><td height="20" width="103" align="right">2,387.5 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Operating income/(loss)</td><td height="20" width="122" align="right">637.3 </td><td height="20" width="103" align="right">(5.8)</td><td height="20" width="103" align="right">(11.3)</td><td height="20" width="103" align="right">620.2 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="19" width="276" align="left"> </td><td height="19" width="122" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Total assets</td><td height="20" width="122" align="right">2,067.1 </td><td height="20" width="103" align="right">1,576.1 </td><td height="20" width="103" align="right">974.3 </td><td height="20" width="103" align="right">4,617.5 </td></tr><tr><td height="20" width="276" align="left">Long-lived assets(3)</td><td height="20" width="122" align="right">202.6 </td><td height="20" width="103" align="right">422.4 </td><td height="20" width="103" align="right">55.6 </td><td height="20" width="103" align="right">680.6 </td></tr><tr><td height="20" width="276" align="left">Capital expenditure on long-lived assets(3)</td><td height="20" width="122" align="right">46.9 </td><td height="20" width="103" align="right">194.4 </td><td height="20" width="103" align="right">18.0 </td><td height="20" width="103" align="right">259.3 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr></table>(1) Stock-based compensation of $65.7 million is included in: Cost of product sales ($4.4 million), Research and development ($20.1 million) and Selling, general and administrative ($41.2 million). (2) Depreciation from manufacturing plants ($21.8 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($15.5 million) is included in Research and development; and all other depreciation and amortization ($204.7 million) is included in Selling, general and administrative. (3) Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments, income tax receivable and financial instruments). <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="36" width="276" align="left"> </td><td height="36" width="122" align="right">Specialty Pharmaceuticals</td><td height="36" width="103" align="right">HGT</td><td height="36" width="103" align="right">All Other</td><td height="36" width="103" align="right">Total</td></tr><tr><td height="20" width="276" align="right">2008 </td><td height="20" width="122" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Product sales</td><td height="20" width="122" align="right">2,272.5 </td><td height="20" width="103" align="right">481.7 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">2,754.2 </td></tr><tr><td height="20" width="276" align="left">Royalties</td><td height="20" width="122" align="right">1.5 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">244.0 </td><td height="20" width="103" align="right">245.5 </td></tr><tr><td height="20" width="276" align="left">Other revenues</td><td height="20" width="122" align="right">8.2 </td><td height="20" width="103" align="right">4.0 </td><td height="20" width="103" align="right">10.3 </td><td height="20" width="103" align="right">22.5 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total revenues</td><td height="20" width="122" align="right">2,282.2 </td><td height="20" width="103" align="right">485.7 </td><td height="20" width="103" align="right">254.3 </td><td height="20" width="103" align="right">3,022.2 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="17" width="276" align="left"> </td><td height="17" width="122" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Cost of product sales(1) (2)</td><td height="20" width="122" align="right">329.0 </td><td height="20" width="103" align="right">58.9 </td><td height="20" width="103" align="right">20.1 </td><td height="20" width="103" align="right">408.0 </td></tr><tr><td height="20" width="276" align="left">Research and development(1) (2)</td><td height="20" width="122" align="right">288.0 </td><td height="20" width="103" align="right">200.3 </td><td height="20" width="103" align="right">6.0 </td><td height="20" width="103" align="right">494.3 </td></tr><tr><td height="20" width="276" align="left">Selling, general and administrative(1) (2)</td><td height="20" width="122" align="right">1,118.5 </td><td height="20" width="103" align="right">172.7 </td><td height="20" width="103" align="right">164.0 </td><td height="20" width="103" align="right">1,455.2 </td></tr><tr><td height="20" width="276" align="left">In-process R&D charge</td><td height="20" width="122" align="right">- </td><td height="20" width="103" align="right">263.1 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">263.1 </td></tr><tr><td height="20" width="276" align="left">Gain on sale of product rights</td><td height="20" width="122" align="right">(20.7)</td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">(20.7)</td></tr><tr><td height="20" width="276" align="left">Integration and acquisition costs</td><td height="20" width="122" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">10.3 </td><td height="20" width="103" align="right">10.3 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total operating expenses</td><td height="20" width="122" align="right">1,714.8 </td><td height="20" width="103" align="right">695.0 </td><td height="20" width="103" align="right">200.4 </td><td height="20" width="103" align="right">2,610.2 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Operating income/(loss)</td><td height="20" width="122" align="right">567.4 </td><td height="20" width="103" align="right">(209.3)</td><td height="20" width="103" align="right">53.9 </td><td height="20" width="103" align="right">412.0 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="19" width="276" align="left"> </td><td height="19" width="122" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Total assets</td><td height="20" width="122" align="right">2,161.2 </td><td height="20" width="103" align="right">1,107.7 </td><td height="20" width="103" align="right">664.8 </td><td height="20" width="103" align="right">3,933.7 </td></tr><tr><td height="20" width="276" align="left">Long-lived assets(3)</td><td height="20" width="122" align="right">192.2 </td><td height="20" width="103" align="right">263.5 </td><td height="20" width="103" align="right">82.1 </td><td height="20" width="103" align="right">537.8 </td></tr><tr><td height="20" width="276" align="left">Capital expenditure on long-lived assets</td><td height="20" width="122" align="right">54.1 </td><td height="20" width="103" align="right">169.5 </td><td height="20" width="103" align="right">30.6 </td><td height="20" width="103" align="right">254.2 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr></table>(1) Stock-based compensation of $65.2 million is included in: Cost of product sales ($3.9 million), Research and development ($18.9 million) and Selling, general and administrative ($42.4 million). (2) Depreciation from manufacturing plants ($16.2 million) and amortization of favorable manufacturing contracts ($1.7 million) is included in Cost of product sales; depreciation of research and development assets ($12.5 million) is included in Research and development; and all other depreciation, amortization and intangible asset impairment charges ($271.9 million) are included in Selling, general and administrative. (3) Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments and financial instruments).<table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="36" width="276" align="left"> </td><td height="36" width="122" align="right">Specialty Pharmaceuticals</td><td height="36" width="103" align="right">HGT</td><td height="36" width="103" align="right">All Other</td><td height="36" width="103" align="right">Total</td></tr><tr><td height="20" width="276" align="right">2007 </td><td height="20" width="122" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td><td height="20" width="103" align="right">$’M</td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Product sales</td><td height="20" width="122" align="right">1,844.5 </td><td height="20" width="103" align="right">325.7 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">2,170.2 </td></tr><tr><td height="20" width="276" align="left">Royalties</td><td height="20" width="122" align="right">1.6 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">245.6 </td><td height="20" width="103" align="right">247.2 </td></tr><tr><td height="20" width="276" align="left">Other revenues</td><td height="20" width="122" align="right">9.5 </td><td height="20" width="103" align="right">4.3 </td><td height="20" width="103" align="right">5.1 </td><td height="20" width="103" align="right">18.9 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total revenues</td><td height="20" width="122" align="right">1,855.6 </td><td height="20" width="103" align="right">330.0 </td><td height="20" width="103" align="right">250.7 </td><td height="20" width="103" align="right">2,436.3 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">___________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="17" width="276" align="left"> </td><td height="17" width="122" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Cost of product sales(1) (2)</td><td height="20" width="122" align="right">263.3 </td><td height="20" width="103" align="right">44.3 </td><td height="20" width="103" align="right">12.7 </td><td height="20" width="103" align="right">320.3 </td></tr><tr><td height="20" width="276" align="left">Research and development(1) (2)</td><td height="20" width="122" align="right">331.1 </td><td height="20" width="103" align="right">213.5 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">544.6 </td></tr><tr><td height="20" width="276" align="left">Selling, general and administrative(1) (2)</td><td height="20" width="122" align="right">895.5 </td><td height="20" width="103" align="right">125.0 </td><td height="20" width="103" align="right">190.1 </td><td height="20" width="103" align="right">1,210.6 </td></tr><tr><td height="20" width="276" align="left">In-process R&D charge</td><td height="20" width="122" align="right">1,866.4 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">1,866.4 </td></tr><tr><td height="20" width="276" align="left">Gain on sale of product rights</td><td height="20" width="122" align="right">(127.8)</td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">(127.8)</td></tr><tr><td height="20" width="276" align="left">Integration and acquisition costs</td><td height="20" width="122" align="right">1.3 </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">- </td><td height="20" width="103" align="right">1.3 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Total operating expenses</td><td height="20" width="122" align="right">3,229.8 </td><td height="20" width="103" align="right">382.8 </td><td height="20" width="103" align="right">202.8 </td><td height="20" width="103" align="right">3,815.4 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="20" width="276" align="left">Operating (loss)/income</td><td height="20" width="122" align="right">(1,374.2)</td><td height="20" width="103" align="right">(52.8)</td><td height="20" width="103" align="right">47.9 </td><td height="20" width="103" align="right">(1,379.1)</td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr><tr><td height="19" width="276" align="left"> </td><td height="19" width="122" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td><td height="19" width="103" align="right"> </td></tr><tr><td height="20" width="276" align="left">Total assets</td><td height="20" width="122" align="right">2,394.5 </td><td height="20" width="103" align="right">586.6 </td><td height="20" width="103" align="right">1,349.0 </td><td height="20" width="103" align="right">4,330.1 </td></tr><tr><td height="20" width="276" align="left">Long-lived assets(3)</td><td height="20" width="122" align="right">174.8 </td><td height="20" width="103" align="right">114.6 </td><td height="20" width="103" align="right">79.2 </td><td height="20" width="103" align="right">368.6 </td></tr><tr><td height="20" width="276" align="left">Capital expenditure on long-lived assets(3)</td><td height="20" width="122" align="right">37.3 </td><td height="20" width="103" align="right">77.5 </td><td height="20" width="103" align="right">27.9 </td><td height="20" width="103" align="right">142.7 </td></tr><tr><td height="11" width="276" align="left"> </td><td height="11" width="122" align="right">_____________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td><td height="11" width="103" align="right">___________</td></tr></table>(1) Stock-based compensation of $75.2 million is included in: Cost of product sales ($5.5 million), Research and development ($17.0 million) and Selling, general and administrative ($52.7 million). (2) Depreciation from manufacturing plants ($11.8 million) and amortization of favorable manufacturing contracts ($1.2 million) is included in Cost of product sales; depreciation of research and development assets ($11.3 million) is included in Research and development; and all other depreciation, amortization and intangible asset impairment charges ($137.1 million) are included in Selling, general and administrative. (3) Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments and financial instruments).Geographic information Revenues (based on the geographic location from which the sale originated): <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2008 </td><td height="17" width="103" align="right">2007 </td></tr><tr><td height="17" width="414" align="left">Year to December 31,</td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left">Ireland </td><td height="17" width="103" align="right">19.5 </td><td height="17" width="103" align="right">17.8 </td><td height="17" width="103" align="right">16.2 </td></tr><tr><td height="17" width="414" align="left">United Kingdom</td><td height="17" width="103" align="right">163.9 </td><td height="17" width="103" align="right">160.0 </td><td height="17" width="103" align="right">177.0 </td></tr><tr><td height="17" width="414" align="left">North America </td><td height="17" width="103" align="right">2,141.3 </td><td height="17" width="103" align="right">2,299.6 </td><td height="17" width="103" align="right">1,798.2 </td></tr><tr><td height="17" width="414" align="left">Rest of World</td><td height="17" width="103" align="right">683.0 </td><td height="17" width="103" align="right">544.8 </td><td height="17" width="103" align="right">444.9 </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left">Total revenues</td><td height="17" width="103" align="right">3,007.7 </td><td height="17" width="103" align="right">3,022.2 </td><td height="17" width="103" align="right">2,436.3 </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr></table>Long-lived assets comprise all non-current assets, (excluding goodwill and other intangible assets, deferred tax assets, investments and financial instruments) based on the geographic location within which the economic benefits arise: <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="17" width="512" align="left"> </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2008 </td></tr><tr><td height="17" width="512" align="left">Year to December 31,</td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td></tr><tr><td height="17" width="512" align="left"> </td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="512" align="left">Ireland </td><td height="17" width="103" align="right">0.7 </td><td height="17" width="103" align="right">1.0 </td></tr><tr><td height="17" width="512" align="left">United Kingdom</td><td height="17" width="103" align="right">79.5 </td><td height="17" width="103" align="right">61.6 </td></tr><tr><td height="17" width="512" align="left">North America </td><td height="17" width="103" align="right">593.5 </td><td height="17" width="103" align="right">468.6 </td></tr><tr><td height="17" width="512" align="left">Rest of World</td><td height="17" width="103" align="right">6.9 </td><td height="17" width="103" align="right">6.6 </td></tr><tr><td height="17" width="512" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="512" align="left">Total </td><td height="17" width="103" align="right">680.6 </td><td height="17" width="103" align="right">537.8 </td></tr><tr><td height="17" width="512" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td></tr></table>Material customers In the periods set out below, certain customers, all within the Specialty Pharmaceuticals operating segment, accounted for greater than 10% of the Company’s total revenues: <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2008 </td><td height="17" width="103" align="right">2008 </td><td height="17" width="103" align="right">2007 </td><td height="17" width="103" align="right">2007 </td></tr><tr><td height="34" width="120" align="left">Year to December 31,</td><td height="34" width="103" align="right">$’M</td><td height="34" width="103" align="right">% revenue</td><td height="34" width="103" align="right">$’M</td><td height="34" width="103" align="right">% revenue</td><td height="34" width="103" align="right">$’M</td><td height="34" width="103" align="right">% revenue</td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="120" align="left">Cardinal Health Inc.</td><td height="17" width="103" align="right">797.0 </td><td height="17" width="103" align="right">27 </td><td height="17" width="103" align="right">888.7 </td><td height="17" width="103" align="right">29 </td><td height="17" width="103" align="right">666.1 </td><td height="17" width="103" align="right">27 </td></tr><tr><td height="17" width="120" align="left">McKesson Corp.</td><td height="17" width="103" align="right">576.3 </td><td height="17" width="103" align="right">19 </td><td height="17" width="103" align="right">674.3 </td><td height="17" width="103" align="right">22 </td><td height="17" width="103" align="right">546.0 </td><td height="17" width="103" align="right">22 </td></tr><tr><td height="9" width="120" align="left"> </td><td height="9" width="103" align="right">____________</td><td height="9" width="103" align="right">___________</td><td height="9" width="103" align="right">___________</td><td height="9" width="103" align="right">___________</td><td height="9" width="103" align="right">___________</td><td height="9" width="103" align="right">___________</td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td width="738" align="left" height="17" colspan="7">Amounts outstanding as at December 31, in respect of these material customers were as follows:</td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2008 </td></tr><tr><td height="17" width="120" align="left">December 31,</td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="120" align="left">Cardinal Health Inc.</td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right">113.0 </td><td height="17" width="103" align="right">72.3 </td></tr><tr><td height="17" width="120" align="left">McKesson Corp.</td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right">82.9 </td><td height="17" width="103" align="right">69.6 </td></tr><tr><td height="7" width="120" align="left"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right">____________</td><td height="7" width="103" align="right">___________</td></tr><tr><td height="17" width="120" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr></table>Revenue by product In the periods set out below, revenues by major product were as follows: <table style="border-collapse: collapse; margin-top: 20px;"><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">2009 </td><td height="17" width="103" align="right">2008 </td><td height="17" width="103" align="right">2007 </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td><td height="17" width="103" align="right">$’M</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="17" width="414" align="left">Specialty Pharmaceuticals</td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="17" width="414" align="left">ADDERALL XR</td><td height="17" width="103" align="right">626.5 </td><td height="17" width="103" align="right">1,101.7 </td><td height="17" width="103" align="right">1,030.9 </td></tr><tr><td height="17" width="414" align="left">VYVANSE</td><td height="17" width="103" align="right">504.7 </td><td height="17" width="103" align="right">318.9 </td><td height="17" width="103" align="right">76.5 </td></tr><tr><td height="17" width="414" align="left">DAYTRANA</td><td height="17" width="103" align="right">71.0 </td><td height="17" width="103" align="right">78.7 </td><td height="17" width="103" align="right">64.2 </td></tr><tr><td height="17" width="414" align="left">EQUASYM </td><td height="17" width="103" align="right">22.8 </td><td height="17" width="103" align="right">- </td><td height="17" width="103" align="right">- </td></tr><tr><td height="17" width="414" align="left">INTUNIV </td><td height="17" width="103" align="right">5.4 </td><td height="17" width="103" align="right">- </td><td height="17" width="103" align="right">- </td></tr><tr><td height="17" width="414" align="left">PENTASA</td><td height="17" width="103" align="right">214.8 </td><td height="17" width="103" align="right">185.5 </td><td height="17" width="103" align="right">176.4 </td></tr><tr><td height="17" width="414" align="left">LIALDA / MEZAVANT</td><td height="17" width="103" align="right">235.9 </td><td height="17" width="103" align="right">140.4 </td><td height="17" width="103" align="right">50.5 </td></tr><tr><td height="17" width="414" align="left">FOSRENOL</td><td height="17" width="103" align="right">184.4 </td><td height="17" width="103" align="right">155.4 </td><td height="17" width="103" align="right">102.2 </td></tr><tr><td height="17" width="414" align="left">CALCICHEW</td><td height="17" width="103" align="right">43.7 </td><td height="17" width="103" align="right">52.8 </td><td height="17" width="103" align="right">54.2 </td></tr><tr><td height="17" width="414" align="left">CARBATROL</td><td height="17" width="103" align="right">82.4 </td><td height="17" width="103" align="right">75.9 </td><td height="17" width="103" align="right">72.3 </td></tr><tr><td height="17" width="414" align="left">REMINYL/REMINYL XL</td><td height="17" width="103" align="right">42.4 </td><td height="17" width="103" align="right">34.4 </td><td height="17" width="103" align="right">31.2 </td></tr><tr><td height="17" width="414" align="left">XAGRID</td><td height="17" width="103" align="right">84.8 </td><td height="17" width="103" align="right">78.7 </td><td height="17" width="103" align="right">66.8 </td></tr><tr><td height="17" width="414" align="left">Other</td><td height="17" width="103" align="right">19.4 </td><td height="17" width="103" align="right">50.1 </td><td height="17" width="103" align="right">119.3 </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">2,138.2 </td><td height="17" width="103" align="right">2,272.5 </td><td height="17" width="103" align="right">1,844.5 </td></tr><tr><td height="8" width="414" align="left"> </td><td height="8" width="103" align="right">____________</td><td height="8" width="103" align="right">___________</td><td height="8" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="17" width="414" align="left">Human Genetic Therapies</td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td><td height="17" width="103" align="right"> </td></tr><tr><td height="17" width="414" align="left">ELAPRASE</td><td height="17" width="103" align="right">353.1 </td><td height="17" width="103" align="right">305.1 </td><td height="17" width="103" align="right">181.8 </td></tr><tr><td height="17" width="414" align="left">REPLAGAL</td><td height="17" width="103" align="right">193.8 </td><td height="17" width="103" align="right">176.1 </td><td height="17" width="103" align="right">143.9 </td></tr><tr><td height="17" width="414" align="left">FIRAZYR</td><td height="17" width="103" align="right">6.1 </td><td height="17" width="103" align="right">0.5 </td><td height="17" width="103" align="right">-</td></tr><tr><td height="17" width="414" align="left">VPRIV</td><td height="17" width="103" align="right">2.5 </td><td height="17" width="103" align="right">- </td><td height="17" width="103" align="right">- </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">555.5 </td><td height="17" width="103" align="right">481.7 </td><td height="17" width="103" align="right">325.7 </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">____________</td><td height="17" width="103" align="right">___________</td><td height="17" width="103" align="right">___________</td></tr><tr><td height="7" width="414" align="left"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right"> </td><td height="7" width="103" align="right"> </td></tr><tr><td height="17" width="414" align="left"> </td><td height="17" width="103" align="right">2,693.7 </td><td height="17" width="103" align="right">2,754.2 </td><td height="17" width="103" align="right">2,170.2 </td></tr><tr><td height="12" width="414" align="left"> </td><td height="12" width="103" align="right">____________</td><td height="12" width="103" align="right">___________</td><td height="12" width="103" align="right">___________</td></tr></table></div>

</NonNumbericText>

<NonNumericTextHeader> 26. Segmental reportingShire’s internal financial reporting is in line with its business unit and </NonNumericTextHeader>

<hasSegments> false </hasSegments>

<hasScenarios> false </hasScenarios>

</Cell>

</Cells>

<ElementDefenition> No definition available. </ElementDefenition>

<ElementReferences> No authoritative reference available. </ElementReferences>

<IsTotalLabel> false </IsTotalLabel>

</Row>

</Rows>

<ComparabilityReport> false </ComparabilityReport>

<HasScenarios> false </HasScenarios>

<MonetaryRoundingLevel> UnKnown </MonetaryRoundingLevel>

<SharesRoundingLevel> UnKnown </SharesRoundingLevel>

<PerShareRoundingLevel> UnKnown </PerShareRoundingLevel>

<HasPureData> false </HasPureData>

</InstanceReport>

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/25/10  SEC                               UPLOAD¶     9/11/17    1:21K  Shire plc
 4/14/10  SEC                               UPLOAD¶     9/11/17    1:31K  Shire plc

↑Top

Filing Submission 0000950103-10-000520 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Shire plc – ‘10-K’ for 12/31/09 – ‘XML.R37’

On: Friday, 2/26/10, at 12:40pm ET · For: 12/31/09 · Accession #: 950103-10-520 · File #: 0-29630

Previous ‘10-K’: ‘10-K’ on 2/27/09 for 12/31/08 · Next: ‘10-K’ on 2/23/11 for 12/31/10 · Latest: ‘10-K’ on 2/20/18 for 12/31/17 · 2 References: By: SEC – ‘UPLOAD’ on 5/25/10 By: SEC – ‘UPLOAD’ on 4/14/10

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34Filing Table of Contents

‘XML.R37’ — Segmental reporting

This Financial Report is an XBRL XML File.

2 Subsequent Filings that Reference this Filing

Previous ‘10-K’: ‘10-K’ on 2/27/09 for 12/31/08 · Next: ‘10-K’ on 2/23/11 for 12/31/10 · Latest: ‘10-K’ on 2/20/18 for 12/31/17 · 2 References:

Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents